Atara Biotherapeutics Inc

Healthcare US ATRA

10.8699USD
-0.8801(7.49%)

Last update at 2024-12-12T19:05:00Z

Day Range

10.7512.08
LowHigh

52 Week Range

6.5039.50
LowHigh

Fundamentals

  • Previous Close 11.75
  • Market Cap73.84M
  • Volume89896
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-162.12499M
  • Revenue TTM62.39M
  • Revenue Per Share TTM12.26
  • Gross Profit TTM 63.57M
  • Diluted EPS TTM-25.32

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -276.11100M -228.29000M -340.09500M -306.60500M -290.96400M
Minority interest - - - - -
Net income -276.12600M -228.30200M -340.14100M -306.62000M -290.97600M
Selling general administrative 50.91M 71.55M 78.80M 64.40M 79.58M
Selling and marketing expenses 1.11M - - - -
Gross profit -0.31300M 49.01M 20.34M -9.86700M -8.10500M
Reconciled depreciation 4.88M 5.65M 9.35M 8.33M 7.07M
Ebit -269.27600M -280.51300M -340.46200M -309.05200M -295.68100M
Ebitda -264.44700M -330.75000M -331.11700M -300.72000M -288.61100M
Depreciation and amortization 4.83M -50.23700M 9.35M 8.33M 7.07M
Non operating income net other - 52.22M 0.37M 2.45M 4.72M
Operating income -269.27600M -280.51300M -340.46200M -309.05200M -295.68100M
Other operating expenses 277.85M 344.09M 360.80M 309.05M 295.68M
Interest expense 5.29M 1.99M 9.71M 10.78M 11.79M
Tax provision 0.00600M 0.01M 0.05M 0.01M 0.01M
Interest income 4.80M 1.99M 0.37M 2.45M 4.72M
Net interest income 0.94M 1.99M 0.37M 2.45M 4.72M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M 0.01M 0.05M 0.01M 0.01M
Total revenue 8.57M 63.57M 20.34M 3.55M 0.00000M
Total operating expenses 268.96M 344.09M 360.80M 309.05M 295.68M
Cost of revenue 8.89M 14.57M 11.38M 9.87M 8.11M
Total other income expense net -6.83500M 52.22M 0.37M 2.45M 4.72M
Discontinued operations - - - - -
Net income from continuing ops -290.24800M -228.30200M -340.14100M -306.62000M -290.97600M
Net income applicable to common shares - -228.30200M -340.14100M -306.62000M -290.97600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 165.50M 376.42M 468.13M 588.12M 342.94M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.18M 10.31M 12.57M 21.36M 13.88M
Total liab 264.74M 249.78M 188.51M 125.78M 52.16M
Total stockholder equity -99.23100M 126.64M 279.61M 462.34M 290.78M
Deferred long term liab - - - - -
Other current liab 48.53M 50.41M 44.91M 40.34M 5.73M
Common stock 0.01M 0.01000M 0.00900M 0.00800M 0.00600M
Capital stock 0.01M 0.01000M 0.00900M 0.00800M 0.00600M
Retained earnings -1969.15000M -1693.02400M -1464.72200M -1124.58100M -817.96100M
Other liab - 109.16M 57.21M 29.69M 1.04M
Good will - - - - -
Other assets 0.00000M 7.02M 3.57M 14.33M 1.77M
Cash 25.99M 92.94M 106.08M 200.40M 74.32M
Cash and equivalents - - - - -
Total current liabilities 142.23M 78.92M 105.79M 82.90M 36.74M
Current deferred revenue 77.83M 8.00M 40.76M 33.45M 21.47M
Net debt 31.89M -21.23800M -80.56600M -187.36300M -60.18100M
Short term debt 12.18M 13.64M 2.75M 1.99M 1.58M
Short long term debt - - - - -
Short long term debt total 57.87M